nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

21.11.2020 | Review Article

Resveratrol and cardiovascular system—the unfulfilled hopes

verfasst von: Małgorzata Chudzińska, Daniel Rogowicz, Łukasz Wołowiec, Joanna Banach, Sławomir Sielski, Robert Bujak, Anna Sinkiewicz, Grzegorz Grześk

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Resveratrol is a natural polyphenolic compound with a stilbene structure endowed with multiple health-promoting effects. Among phenolic compounds, resveratrol is assigned a leading role in the health-promoting effects of red wine.

Methods

The aim of the study was to assess the effect of resveratrol on the cardiovascular system in the experimental and clinical studies conducted so far. Moreover, the paper discusses the results of the most recent meta-analyses assessing resveratrol’s therapeutic effect on the cardiovascular system in humans.

Results

In animal and preclinical studies, resveratrol has demonstrated a wide physiological and biochemical spectrum of activity, including antioxidant, anti-inflammatory, antiplatelet, and anticoagulant activities, which translated into its health-promoting effects on the cardiovascular system. The performed meta-analyses allow to confirm such an impact, however, after the assessment with the use of the SYRCLE’s tool, these studies are burdened with a high risk of bias, and the results are not clearly presented.

Conclusion

Despite numerous articles and clinical studies, the convincing beneficial mechanisms of resveratrol as well as its health-promoting effects in cardiovascular diseases have not been clearly confirmed in humans. Therefore, there is a need for further clinical studies, especially randomized, double-blind, placebo-controlled trials to objectively confirm the possible health-promoting effects of this substance and to determine both the efficacy and safety, and possible therapeutic potential.

Trela BC, Waterhouse AL (1996) Resveratrol Isomeric molar absorptivities and stability. J Agric Food Chem 44:1253–1257. https://doi.org/10.1021/jf9504576CrossRef

Pantusa M, Bartucci R, Rizzuti B (2014) Stability of trans-resveratrol associated with transport proteins. J Agric Food Chem 62:4384–4391. https://doi.org/10.1021/jf405584aCrossRefPubMed

Gambini J, Inglés M, Olaso G et al (2015) Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. https://doi.org/10.1155/2015/837042

Takaoka M (1939) Resveratrol, a new phenolic compound, from Veratrum grandiflorum. Nippon Kagaku Kaishi (J Chem Soc Jpn) 60:1090–1100. https://doi.org/10.1246/nikkashi1921.60.1090CrossRef

Burns J, Yokota T, Ashihara H et al (2002) Plant foods and herbal sources of resveratrol. J Agric Food Chem 50:3337–3340. https://doi.org/10.1021/jf0112973CrossRefPubMed

Sales JM, Resurreccion AV (2014) Resveratrol in peanuts. Crit Rev Food Sci Nutr 54:734–770. https://doi.org/10.1080/10408398.2011.606928CrossRefPubMed

Counet C, Callemien D, Collin S (2006) Chocolate and cocoa: new sources of trans-resveratrol and trans-piceid. Food Chem 98:649–657. https://doi.org/10.1016/j.foodchem.2005.06.030CrossRef

Presta MA, Bruyneel B, Zanella R et al (2009) Determination of Flavonoids and Resveratrol in Wine by Turbulent-Flow Chromatography-LC-MS. Chromatographia 69:167–173. https://doi.org/10.1365/s10337-009-1132-xCrossRefPubMedPubMedCentral

Walle T, Hsieh F, DeLegge MH et al (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377–1382. https://doi.org/10.1124/dmd.104.000885CrossRefPubMed

10.

Smoliga JM, Blanchard O (2014) Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules 19:17154–17172. https://doi.org/10.3390/molecules191117154CrossRefPubMedPubMedCentral

11.

Bonnefont-Rousselot D (2016) Resveratrol and cardiovascular diseases. Nutrients 8:250. https://doi.org/10.3390/nu8050250CrossRefPubMedCentral

12.

Breuss JM, Atanasov AG, Uhrin P (2019) Resveratrol and its effects on the vascular system. Int J Mol Sci 20:1523. https://doi.org/10.3390/ijms20071523CrossRefPubMedCentral

13.

Cheng CK, Luo JY, Lau CW (2020) Pharmacological basis and new insights of resveratrol action in the cardiovascular system. Br J Pharmacol 177:1258–1277. https://doi.org/10.1111/bph.14801CrossRefPubMed

14.

Yashiro T, Nanmoku M, Shimizu M et al (2012) Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. Atherosclerosis 220:369–374. https://doi.org/10.1016/j.atherosclerosis.2011.11.006CrossRefPubMed

15.

Berrougui H, Grenier G, Loued S et al (2009) A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 207:420–427. https://doi.org/10.1016/j.atherosclerosis.2009.05.017CrossRefPubMed

16.

Sahebkar A (2013) Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71:822–835. https://doi.org/10.1111/nure.12081CrossRefPubMed

17.

Vislocky LM, Fernandez ML (2010) Biomedical effects of grape products. Nutr Rev 68:656–670. https://doi.org/10.1111/j.1753-4887.2010.00335.xCrossRefPubMed

18.

Xia N, Daiber A, Forstermann U, Li H (2017) Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol 174:1633–1646. https://doi.org/10.1111/bph.13492CrossRefPubMed

19.

Frombaum M, Le Clanche S, Bonnefont-Rousselot D et al. (2012) Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and‚ NO bioavailability: potential benefits to cardiovascular diseases. Biochimie 94:269–276. https://doi.org/10.1016/j.biochi.2011.11.001

20.

Wang Z, Huang Y, Zou J (2002) Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 9:77–79. https://doi.org/10.3892/ijmm.9.1.77CrossRefPubMed

21.

Pace-Asciak CR, Hahn S, Diamandis EP (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235:207–219. https://doi.org/10.1016/0009-8981(95)06045-1CrossRefPubMed

22.

Bertelli AA, Giovannini L, Giannessi DA et al. (1995) Antiplatelet activity of synthetic and natural resveratrol in red wine. NIH National library of medicine. https://pubmed.ncbi.nlm.nih.gov/7499059/. Accessed 03 November 2020

23.

Ghanim H, Sia CL, Korzeniewski K et al (2011) A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 96:1409–1414. https://doi.org/10.1210/jc.2010-1812CrossRefPubMedPubMedCentral

24.

Malaguarnera L (2019) Influence of resveratrol on the immune response. Nutrients 11:946. https://doi.org/10.3390/nu11050946CrossRefPubMedCentral

25.

Das S, Das DK (2007) Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets 6:168–173. https://doi.org/10.2174/187152807781696464CrossRefPubMed

26.

Wallerath T, Deckert G, Ternes T et al (2002) Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106:1652–1658. https://doi.org/10.1161/01.CIR.0000029925.18593.5CCrossRefPubMed

27.

Leikert JF, Räthel TR, Wohlfart P et al (2002) Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 106:1614–1617. https://doi.org/10.1161/01.CIR.0000034445.31543.43CrossRefPubMed

28.

Takahashi S, Nakashima Y (2012) Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. Br J Nutr 107:774–780. https://doi.org/10.1017/S0007114511003588CrossRefPubMed

29.

Cheng AS, Cheng YH, Lee CY et al (2015) Resveratrol protects against methylglyoxal-induced hyperglycemia and pancreatic damage in vivo. Nutrients 7:2850–2865. https://doi.org/10.3390/nu7042850CrossRefPubMedPubMedCentral

30.

Szkudelski T, Szkudelska K (2015) Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta 1852:1145–1154. https://doi.org/10.1016/j.bbadis.2014.10.013CrossRefPubMed

31.

Hausenblas HA, Schoulda JA, Smoliga JM (2015) Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus: systematic review and meta-analysis. Mol Nutr Food Res 59:147–159. https://doi.org/10.1002/mnfr.201400173CrossRefPubMed

32.

Kong W, Chen LL, Zheng J et al (2015) Resveratrol supplementation restores high-fat diet-induced insulin secretion dysfunction by increasing mitochondrial function in islet. Exp Biol Med 240:220–229. https://doi.org/10.1177/1535370214548998CrossRef

33.

Andrade EF, Orlando DR, Araújo AMS et al (2019) Can resveratrol treatment control the progression of induced periodontal disease? A systematic review and meta-analysis of preclinical studies. Nutrients 11:953. https://doi.org/10.3390/nu11050953CrossRefPubMedCentral

34.

Chen JY, Zhu Q, Zhang S et al (2019) Resveratrol in experimental Alzheimer’s disease models: A systematic review of preclinical studies. Pharmacol Res 150:104476. https://doi.org/10.1016/j.phrs.2019.104476CrossRefPubMed

35.

Toro MD, Nowomiejska K, Avitabile T et al (2019) Effect of Resveratrol on In Vitro and In Vivo Models of Diabetic Retinophathy: A Systematic Review. Int J Mol Sci 20:3503. https://doi.org/10.3390/ijms20143503CrossRefPubMedCentral

36.

Akbari M, Tamtaji OR, Lankarani KB (2019) The effects of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev 26:305–319. https://doi.org/10.1007/s40292-019-00324-6CrossRefPubMed

37.

Heilbronn LK, Ravussin E (2003) Calorie restriction and aging: review of the literature and implication for studies in humans. Am J Clin Nutr 78:361–369. https://doi.org/10.1093/ajcn/78.3.361CrossRefPubMed

38.

Das DK, Mukherjee S, Ray D (2010) Resveratrol and red wine, healthy heart and longevity. Heart Failure Reviews 15:467–477. https://doi.org/10.1007/s10741-010-9163-9CrossRefPubMed

39.

Lee SH, Lee JH, Lee HY et al (2019) Sirtuin signaling in cellular senescence and aging. BMB Rep 52:24–34. https://doi.org/10.5483/BMBRep.2019.52.1.290CrossRefPubMedPubMedCentral

40.

Cao D, Wang M, Qiu X et al (2015) Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev 29:1316–1325. https://doi.org/10.1101/gad.265462.115CrossRefPubMedPubMedCentral

41.

Porcu M, Chiarugi A (2005) The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci 26:94–103. https://doi.org/10.1016/j.tips.2004.12.009CrossRefPubMed

42.

Fernandez-Quintela A, Milton-Laskibar I, Gonzalez M et al (2017) Antiobesity effects of resveratrol: which tissues are involved? Ann N Y Acad Sci 403:118–131. https://doi.org/10.3389/fendo.2019.00413CrossRef

43.

Tabrizi R, Tamtaji OR, Lankarani KB (2018) The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 13:1–16. https://doi.org/10.1080/10408398.2018.1529654CrossRef

44.

Zhao Y, Chen B, Shen J (2017) The beneficial effects of quercetin, curcumin, and resveratrol in obesity. Oxid Med Cell Longev 2017:1459497. https://doi.org/10.1155/2017/1459497CrossRefPubMedPubMedCentral

45.

Li YR, Li S, Lin CC (2018) Effect of resveratrol and pterostilbene on aging and longevity. Biofactors 44:69–82. https://doi.org/10.1002/biof.1400CrossRefPubMed

46.

Bastianetto S, Ménard C, Quirion R (2015) Neuroprotective action of resveratrol. Biochimica et Biophysica Acta 6:1195–1201. https://doi.org/10.1016/j.bbadis.2014.09.011CrossRef

47.

Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382. https://doi.org/10.1074/jbc.M508246200CrossRefPubMed

48.

Zhu X, Li W, Li Y (2019) The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition. Neuropharmacology 15;153:20–31. https://doi.org/10.1016/j.neuropharm.2019.04.022

49.

Lange KW, Li S (2018) Resveratrol, pterostilbene, and dementia. Biofactors 44:83–90. https://doi.org/10.1002/biof.1396CrossRefPubMed

50.

Cicero AFG, Ruscica M, Banach M (2019) Resveratrol and cognitive decline: a clinician perspective. Arch Med Sci 15:936–943. https://doi.org/10.5114/aoms.2019.85463CrossRefPubMedPubMedCentral

51.

Bhullar KS, Hubbard BP (2015) Lifespan and healthspan extension by resveratrol. Biochim. Biophys Acta 1852:1209–1218. https://doi.org/10.1016/j.bbadis.2015.01.012CrossRef

52.

Hector KL, Lagisz M, Nakagawa S (2012) The effect of resveratrol on longevity across species: a meta-analysis. Biology Letters 8:790–793. https://doi.org/10.1098/rsbl.2012.0316CrossRefPubMedPubMedCentral

53.

Fogacci F, Tocci G, Presta V et al (2019) Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr 59:1605–1618. https://doi.org/10.1080/10408398.2017.1422480CrossRefPubMed

54.

Liu Y, Ma W, Zhang P et al (2015) Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 34:27–34. https://doi.org/10.1016/j.clnu.2014.03.009CrossRefPubMed

55.

Mousavi SM, Milajerdi A, Sheikhi A et al (2019) Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. Obes Rev 20:487–498. https://doi.org/10.1111/obr.12775CrossRefPubMed

56.

Tabrizi R, Tamtaji OR, Lankarani K et al (2020) The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 60:375–390. https://doi.org/10.1080/10408398.2018.1529654CrossRefPubMed

57.

Zhu X, Wu C, Qiu S (2017) Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr Metab 14:60. https://doi.org/10.1186/s12986-017-0217-zCrossRef

58.

Haghighatdoost F, Hariri M (2018) Effect of resveratrol on lipid profile: an updated systematic review and meta-analysis on randomized clinical trials. Pharmacol Res 129:141–150. https://doi.org/10.1016/j.phrs.2017.12.033CrossRefPubMed

59.

Kjaer TN, Ornstru MJ, Poulsen MM et al (2017) No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab 102:1642–1651. https://doi.org/10.1210/jc.2016-2160CrossRefPubMed

60.

Haghighatdoost F, Hariri M (2019) Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials. Eur J Clin Nutr 73:345–355. https://doi.org/10.1038/s41430-018-0253-4CrossRefPubMed

61.

Koushki M, Dashatan NA, Meshkani R (2018) Effect of resveratrol supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Clin Ther 40:1180–1192. https://doi.org/10.1016/j.clinthera.2018.05.015CrossRefPubMed

62.

Sahebkar A, Serban C, Ursoniu S et al (2015) Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors–results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 189:47–55. https://doi.org/10.1016/j.ijcard.2015.04.008CrossRefPubMed

63.

Magyar K, Halmosi R, Palfi A et al (2012) Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 50:179–187. https://doi.org/10.3233/CH-2011-1424CrossRefPubMed

64.

Raj P, Zieroth S, Netticadan T (2015) An overview of the efficacy of resveratrol in the management of ischemic heart disease. Ann N Y Acad Sci 1348:55–67. https://doi.org/10.1111/nyas.12828CrossRefPubMed

65.

Raj P, Louis XL, Thandapilly SJ et al (2014) Potential of resveratrol in the treatment of heart failure. Life Sci 95:63–71. https://doi.org/10.1016/j.lfs.2013.12.011CrossRefPubMed

66.

Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523–1526. https://doi.org/10.1016/0140-6736(92)91277-fCrossRefPubMed

67.

Stervbo U, Vang O, Bonnesen C (2007) A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem 101:449–457. https://doi.org/10.1016/j.foodchem.2006.01.047CrossRef

68.

Pastor RF, Restani P, Di Lorenzo C (2019) Resveratrol, human health and winemaking perspectives. Crit Rev Food Sci Nutr 59:1237–1255. https://doi.org/10.1016/j.foodchem.2006.01.047CrossRefPubMed

69.

Chow HH, Garland LL, Hsu CH et al (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168–1175. https://doi.org/10.1158/1940-6207.CAPR-09-0155CrossRef

70.

Brasnyó P, Molnár GA, Mohás M et al (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106:383–389. https://doi.org/10.1017/S0007114511000316CrossRefPubMed

71.

Jeandet P, Bessis R, Maume BF et al (1993) Analysis of resveratrol in burgundy wines. J Wine Res 4:79. https://doi.org/10.1080/09571269308717954CrossRef

72.

Romero-Pérez AI, Lamuela-Raventós RM, Buxaderas S (1996) Torre-Boronat MC. Resveratrol and piceid as varietal markers of white wines. J Agric Food Chem 44:1975–1978. https://doi.org/10.1080/09571269308717954CrossRef

73.

Cvejic JM, Djekic SV, Petrovic AV (2010) Determination of trans- and cis-resveratrol in Serbian commercial wines. J Chromatogr Sci 48:229–234. https://doi.org/10.1080/09571269308717954CrossRefPubMed

74.

Global Agricultural Information Network (2015) Wine Annual Report and Statistics 2015 (GAIN Report Number IT1512) https://apps.fas.usda.gov/newgainapi/api/report/downloadreportbyfilename?filename=Wine%20Annual_Rome_EU-28_3-16-2015.pdf.

75.

Dudley J, Das S, Mukherjee S et al (2009) Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 20:443–452. https://doi.org/10.1016/j.jnutbio.2008.05.003CrossRefPubMed

76.

Pezzuto JM (2019) Resveratrol: twenty years of growth, development and controversy. Biomol Ther (Seoul) 27:1–14. https://doi.org/10.4062/biomolther.2018.176CrossRef

Titel: Resveratrol and cardiovascular system—the unfulfilled hopes
verfasst von: Małgorzata Chudzińska
Daniel Rogowicz
Łukasz Wołowiec
Joanna Banach
Sławomir Sielski
Robert Bujak
Anna Sinkiewicz
Grzegorz Grześk
Publikationsdatum: 21.11.2020
Verlag: Springer International Publishing
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 3/2021
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-020-02441-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Impact of changes in community psychiatric service provision on mental health presentations to the emergency department

Objective evaluation of the nasal mucosal secretion in COVID-19 patients with anosmia

Reproductive surrogacy in Ireland — an ethical and legal context

Trends in HbA1c and other biochemical outcomes of individuals with newly diagnosed type 1 diabetes

Effect of long-term acid suppression therapy with proton pump inhibitors or H2 receptor blockers on serum vitamin B12 levels in elderly population

The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis